MARKET

RGNX

RGNX

Regenxbio
NASDAQ
26.43
+1.51
+6.06%
After Hours: 26.43 0 0.00% 17:00 09/30 EDT
OPEN
25.08
PREV CLOSE
24.92
HIGH
27.20
LOW
25.00
VOLUME
487.43K
TURNOVER
0
52 WEEK HIGH
44.35
52 WEEK LOW
18.69
MARKET CAP
1.14B
P/E (TTM)
20.30
1D
5D
1M
3M
1Y
5Y
REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference
REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present in a fireside chat at Chardan's 6th Annual Genetic Medicines Conference on Tuesday, October 4th, 2022:
PR Newswire · 4d ago
REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting
REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held September 30-October 3, 2022 in Chicago, IL. The presentations will highlight new and encore data for RGX-314, an inve...
PR Newswire · 5d ago
What 4 Analyst Ratings Have To Say About Regenxbio
Within the last quarter, Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings:
Benzinga · 09/09 16:24
Morgan Stanley Maintains Overweight on Regenxbio, Raises Price Target to $52
Morgan Stanley analyst Vikram Purohit maintains Regenxbio (NASDAQ:RGNX) with a Overweight and raises the price target from $46 to $52.
Benzinga · 09/09 13:08
Morgan Stanley Raises REGENXBIO's Price Target to $52 From $46, Maintains Overweight Rating
Morgan Stanley Raises REGENXBIO's Price Target to $52 From $46, Maintains Overweight Rating
MT Newswires · 09/09 09:35
--Morgan Stanley Boosts Price Target on REGENXBIO to $52 From $46, Maintains Overweight Rating
--Morgan Stanley Boosts Price Target on REGENXBIO to $52 From $46, Maintains Overweight Rating
MT Newswires · 09/09 08:53
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
PR Newswire · 09/06 11:05
REGENXBIO shares more data for Hunter Syndrome candidate
REGENXBIO Inc. (NASDAQ:RGNX), a biotech focused on gene therapies, annou...
Seekingalpha · 08/31 12:07
More
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company focused on providing curative potential of gene therapy. The Company's investigational gene therapies are designed to deliver functional genes to address genetic defects in cells. Its investigational AAV Therapeutics include: RGX-314, which is developing in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases characterized by loss of vision; RGX-202, which is developing to treat Duchenne muscular dystrophy (Duchenne), one of the most common fatal genetic disorders affecting children; RGX-121, RGX-111 and RGX-181, which is developing to treat Mucopolysaccharidosis type II (MPS II), Mucopolysaccharidosis type I (MPS I), and late infantile neuronal ceroid lipofuscinosis type II (CLN2 disease)., and RGX-381, which is developing to treat the ocular manifestations of CLN2 disease.

Webull offers kinds of Regenxbio Inc stock information, including NASDAQ:RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.